AbbVie
Q4 2022 Earnings Call
Feb 09, 2023, 9:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good morning. Thank you for standing by. Welcome to the AbbVie fourth quarter 2022 earnings conference call. [Operator instructions] I would now like to turn -- introduce the call to Ms.
Liz Shea, senior vice president of investor relations. You may proceed.
Liz Shea -- Vice President, Investor Relations
Good morning and thanks for joining us. Also on the call with me today are Rick Gonzalez, chairman of the board and chief executive officer; Rob Michael, vice chairman and president; Jeff Stewart, executive vice president, chief commercial officer; Carrie Strom, senior vice president and president, allergan aesthetics; and Tom Hudson, senior vice president, R&D, and chief scientific officer. Joining us for the Q&A portion of the call are Scott Reents, senior vice president and chief financial officer; and Roopal Thakkar, vice president, global regulatory affairs. Before we get started, I'll note that some statements we make today may be considered forward-looking statements based on our current expectations.
AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings. AbbVie undertakes no obligation to update these forward-looking statements except as required by law. On today's conference call, non-GAAP financial measures will be used to help investors understand Abbvie's business performance.
These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Following our prepared remarks, we'll take your questions. So, with that, I'll now turn the call over to Rick.
Rick Gonzalez -- Chairman and Chief Executive Officer
Thank you, Liz. Good morning, everyone, and thank you for joining us today. I'll provide perspective on our overall performance and outlook and then Jeff, Carrie, Tom, and Rob for your business highlights, pipeline progress, financial results, and 2023 guidance in more detail. Today, we reported another strong quarter and a highly productive year for AbbVie.
We delivered full year 2022 adjusted earnings per share of $13.77, reflecting double-digit growth. Total net revenues of more than $58 billion were up 5.1% on an operational basis, driven by impressive growth from Skyrizi and Rinvoq, which generated nearly $7.7 billion of combined sales in 2022. As I reflect on our 10 years as an independent company, we have made excellent progress evolving AbbVie into a leading biopharmaceutical company. We have successfully created a well-diversified portfolio with multiple growth platforms in attractive and sustainable markets.